Larimar Therapeutics (LRMR) Current Assets (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Current Assets for 14 consecutive years, with $160.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 10.39% year-over-year to $160.7 million; the trailing twelve-month figure through Jun 2026 stood at $160.7 million (up 10.39% YoY), and the FY2025 full-year result was $142.0 million, down 27.28% from the prior year.
• Current Assets climbed to $160.7 million in Q2 2026 per LRMR's latest filing, from $142.0 million in the prior quarter.
• Across five years, Current Assets topped out at $231.1 million in Q2 2024 and bottomed at $56.7 million in Q2 2022.
• Historically, Current Assets has averaged $143.9 million across 5 years, with a median of $142.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Current Assets jumped 117.07% in 2024, then slumped 37.02% in 2025.
• Over 5 years, Current Assets stood at $120.7 million in 2022, then slipped by 25.31% to $90.2 million in 2023, then surged by 116.58% to $195.3 million in 2024, then slipped by 27.28% to $142.0 million in 2025, then grew by 13.13% to $160.7 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $160.7 million, $142.0 million, and $183.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.